1. Clinical Overview
Paclitaxel is a mitotic inhibitor and antineoplastic agent derived from the bark of the Pacific yew tree (Taxus brevifolia). It is a microtubule-stabilizing agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability inhibits the normal dynamic reorganization of the microtubule network essential for vital interphase and mitotic cellular functions. In the Indian context, it is a cornerstone of chemotherapy regimens for various solid tumors, available as a concentrate for solution for infusion, often requiring specialized oncology centers for administration due to its significant toxicity profile and need for premedication.
| Onset | Duration | Bioavailability |
|---|---|---|
| Cytotoxic effects begin upon cellular entry and binding to microtubules; clinical tumor response is typically observed over weeks to months of treatment cycles. | The pharmacological effect persists for the duration of the cell cycle disruption; dosing intervals are typically every 3 weeks (or weekly in some regimens) based on bone marrow recovery. | Not applicable. Administered exclusively via intravenous infusion; oral bioavailability is negligible. |
2. Mechanism of Action
Paclitaxel binds specifically and reversibly to the beta-tubulin subunit of microtubules, enhancing microtubule assembly and stabilizing the polymerized structure. It shifts the dynamic equilibrium between tubulin dimers and microtubules toward assembly, leading to the formation of abnormally stable and non-functional microtubule bundles throughout the cell cycle. This disrupts the normal microtubule dynamics required for vital cellular processes, particularly during mitosis.
3. Indications & Uses
- Metastatic Carcinoma of the Ovary (as first-line and subsequent therapy)
- Metastatic Breast Cancer (after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy)
- Non-Small Cell Lung Cancer (NSCLC) (first-line, in combination with a platinum agent, in patients who are not candidates for curative surgery/radiation)
- Adenocarcinoma of the Pancreas (as first-line treatment in combination with gemcitabine)
- Kaposi's Sarcoma (AIDS-related, second-line therapy)
4. Dosage & Administration
Adult Dosage: Dose is based on body surface area (BSA). Common regimens: 1) **Every-3-week schedule:** 175 mg/m² IV over 3 hours. 2) **Weekly schedule:** 80-100 mg/m² IV over 1 hour. The 300mg vial is a common strength for convenient reconstitution based on BSA calculations.
Administration: 1. **Premedication:** Administer approximately 30-60 minutes prior: Dexamethasone (20 mg PO/IV), Diphenhydramine (50 mg IV), and Ranitidine/Famotidine (50 mg IV). 2. **Dilution:** Dilute concentrate with 0.9% Sodium Chloride Injection, or 5% Dextrose Injection, or 5% Dextrose and 0.9% Sodium Chloride Injection to a final concentration of 0.3 to 1.2 mg/mL. 3. **Infusion:** Administer via a non-PVC (polyethylene-lined) infusion set using an in-line filter (0.22 micron). Infuse over 3 hours (standard) or 1 hour (weekly). 4. **Monitoring:** Continuous monitoring for hypersensitivity reactions during first 30 minutes and frequent vital signs. Monitor CBC regularly.
5. Side Effects
Common side effects may include:
- Bone Marrow Suppression: Neutropenia (dose-limiting), anemia, thrombocytopenia
- Alopecia (nearly universal)
- Peripheral Sensory Neuropathy (numbness, tingling, pain in hands/feet)
- Myalgia/Arthralgia
- Nausea/Vomiting (mild to moderate)
- Diarrhea
- Mucositis
- Hypersensitivity Reactions (despite premedication: flushing, rash, dyspnea)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Cisplatin | Sequence matters. Administering cisplatin BEFORE paclitaxel increases severity of myelosuppression. Paclitaxel should be given BEFORE cisplatin to minimize toxicity. | Major |
| Doxorubicin | Paclitaxel reduces the clearance of doxorubicin, increasing its plasma levels and risk of cardiotoxicity (congestive heart failure). | Major |
| Ketoconazole, Itraconazole, Clarithromycin | Strong CYP3A4 inhibitors; may decrease paclitaxel metabolism, increasing its plasma concentration and risk of toxicity. | Moderate |
| Rifampicin, Phenytoin, Carbamazepine | CYP3A4/CYP2C8 inducers; may increase paclitaxel metabolism, decreasing its plasma concentration and potentially reducing efficacy. | Moderate |
| Live Vaccines (e.g., MMR, Varicella) | Risk of severe or fatal infection due to immunosuppression. Avoid. | Major |
7. Patient Counselling
- DO complete the full course of premedication as prescribed.
- DO report any signs of infection (fever, chills, sore throat) immediately.
- DO maintain good oral hygiene to reduce risk of mucositis.
- DO use effective contraception during and after treatment.
- DO NOT receive any vaccinations without consulting your oncologist.
- DO NOT take any new medications, including OTC drugs, herbal supplements (especially St. John's Wort), or vitamins without consulting your doctor.
- DO NOT consume grapefruit or its juice during therapy.
8. Toxicology & Storage
Overdose: Exaggeration of primary toxicities: Severe bone marrow suppression (profound neutropenia, thrombocytopenia, anemia), severe mucositis, severe peripheral neuropathy, acute cardiotoxicity (bradycardia, conduction blocks), and severe hypersensitivity reactions.
Storage: Store the unopened vials at a temperature between 2°C to 8°C (36°F to 46°F). Retain in the original package to protect from light. Do not freeze. The diluted solution for infusion is stable at room temperature (approx. 25°C) and ambient lighting for up to 27 hours. However, due to the risk of microbial contamination, it is recommended to use the infusion solution immediately after preparation. Discard any unused portion. Handle as cytotoxic material; follow institutional guidelines for safe disposal.